Previous close | 3.6500 |
Open | 3.6900 |
Bid | 3.8100 x 400 |
Ask | 3.8600 x 500 |
Day's range | 3.6450 - 3.9200 |
52-week range | 1.8100 - 11.3100 |
Volume | |
Avg. volume | 303,111 |
Market cap | 230.706M |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.0800 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.80 |
Explore key insights from Acumen Pharmaceuticals' Q1 2024 earnings, focusing on their innovative Alzheimer's treatments and financial outlook.
Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027Company to host conference call and webcast today at 8:00 a.m. ET CHAR